USA flag logo/image

An Official Website of the United States Government

High Dimensional Cytometric Assay for Clinical Assessment of Vascular Health

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43HL114147
Solicitation Year:
2013
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA12-088
Small Business Information
CYTOVAS, LLC
3160 CHESTNUT STREET SUITE 200 PHILADELPHIA, PA 19104-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: High Dimensional Cytometric Assay for Clinical Assessment of Vascular Health
Agency: HHS
Contract: 1R43HL114147-01A1
Award Amount: $271,295.00
 

Abstract:

DESCRIPTION (provided by applicant): Atherosclerotic disease is a prevalent and progressive condition that can be difficult to assess during sub- clinical stages. A developing and exciting biomarker strategy is the measurement of microparticles (MPs) and assessment of circulating progenitor and mature endothelial cells. All eukaryotic cells shed MPs in response to activation or apoptosis. Elevation of plasma MPs, particularly those of endothelial origin, reflect cellular injury and is a surrogate marker forvascular dysfunction. MPs have been enumerated in a number of conditions where vascular dysfunction and inflammation are important pathophysiological mechanisms, for example coronary artery disease or thrombotic microangiopathies. We recently completed apilot study evaluating levels of MPs in patients with diabetes mellitus and compared flow cytometry results with those of a non cell specific Enzyme Linked ImmunoSorbent assay (ELISA). The ELISA assay results correlated with flow cytometry results but didnot distinguish the cell of origin where the micoparticle originated. Cytovas' overall goal is to develop and validate a novel highthroughput, high content, flow cytometric assay, using a unique biocomputational approach, that will measure cellular and subcellular that provide a signature for individuals at cardiovascular risk. For this study, we will develop the MP component via the following specif aims: 1) Refine the procedures for reproducible detection of MPs using flow cytometry; and 2) Derive a computational analysis paradigm for clinical implementation. Such a high throughput, high information content approach may prove clinically useful for stratifying cardiovascular risk among patients, in guiding and monitoring response to therapy, and in developing new therapeutic and preventive approaches. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This proposal will provide a new way to manage healthcare for people with, or at risk of, certain heart and blood vessel diseases (such as atherosclerosis). Presently, healthcare for these people relies on the development of symptoms, by which time options are limited. The product that will be developed here will help to evaluate risk before symptoms develop, guide treatment decisions, and assess response to treatment.

Principal Investigator:

Todd R. Johnson
859-323-3162
todd.johnson@cytovas.com

Business Contact:

Emile M. Md
215-662-3275
Emile.Mohler@uphs.upenn.edu
Small Business Information at Submission:

CYTOVAS, LLC
3160 CHESTNUT STREET SUITE 200 PHILADELPHIA, PA 19104-

EIN/Tax ID: 127363999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No